Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 11:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 711 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Atopy Clear all
Completed Phase 2 Interventional

The Role of Topically Dissolved Oxygen (TDO) to Ameliorate Signs of Photodamage

NCT00991198
View directory record Official record
Conditions
Rosacea, Acne Vulgaris, Atopic Dermatitis, Seborrheic Dermatitis
Interventions
Topical oxygen, placebo
Drug
Lead sponsor
Aria Aesthetics Inc.
Industry
Eligibility
25 Years to 60 Years · Female only
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 8, 2011 · Synced Oct 23, 2026, 11:52 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Evaluation of Topical B12 for the Treatment of Childhood Atopic Dermatitis

NCT00465699
View directory record Official record
Conditions
Eczema
Interventions
Topical B12 0.07%
Drug
Lead sponsor
Spartanburg Regional Healthcare System
Other
Eligibility
6 Months to 18 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Spartanburg, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 25, 2007 · Synced Oct 23, 2026, 11:52 AM EDT
Completed Phase 4 Interventional

Bilateral Comparison Study of Elidel 1% and Hylatopic Plus Emollient Foam for the Treatment of Subjects With Atopic Dermatitis

NCT01202149
View directory record Official record
Conditions
Eczema, Atopic Dermatitis
Interventions
Elidel (pimecrolimus cream, 1%) Hylatopic Plus Emollient Foam (non-medicated device)
Device
Lead sponsor
Frankel, Amylynne, M.D.
Other
Eligibility
2 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 15, 2011 · Synced Oct 23, 2026, 11:52 AM EDT
Not listed Phase 4 Interventional

Dupilmuab for Atopic Dermatitis Monitored With Noninvasive Imaging.

NCT05265234
View directory record Official record
Conditions
Eczema, Atopic Dermatitis
Interventions
Dupilumab, Optical Coherence Tomography, Reflectance confocal microscopy
Drug · Device
Lead sponsor
OptiSkin Medical
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 3, 2022 · Synced Oct 23, 2026, 11:52 AM EDT
Completed Phase 2 Interventional

An Evaluation of PDI-192 0.1% in Comparison to PDI-192 0.15% in the Treatment of Mild to Moderate Atopic Dermatitis

NCT01826461
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
PDI-192, Vehicle
Drug
Lead sponsor
PreCision Dermatology, Inc.
Industry
Eligibility
3 Months to 17 Years
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
9
States / cities
San Diego, California • Chicago, Illinois • Normal, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated May 29, 2014 · Synced Oct 23, 2026, 11:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate ASN008 Topical Gel (TG)

NCT03798561
View directory record Official record
Conditions
Dermatitis, Atopic, Pruritus, Dermatitis Eczema
Interventions
ASN008 TG, Placebo TG
Drug
Lead sponsor
Asana BioSciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
4
States / cities
Cortland, New York • High Point, North Carolina • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Oct 23, 2026, 11:52 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY3872386 in Healthy Participants and Participants With Atopic Dermatitis

NCT06119529
View directory record Official record
Conditions
Healthy, Atopic Dermatitis
Interventions
LY3872386, Prednisone, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
2
States / cities
Anaheim, California • Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Oct 3, 2025 · Synced Oct 23, 2026, 11:52 AM EDT
Completed Phase 3 Interventional Results available

Study of Ruxolitinib Cream in Adolescents With Atopic Dermatitis

NCT05456529
View directory record Official record
Conditions
Atopic Dermatitis (AD)
Interventions
Ruxolitinib Cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
12 Years to 17 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
26
States / cities
North Little Rock, Arkansas • Fountain Valley, California • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2025 · Synced Oct 23, 2026, 11:52 AM EDT
Active, not recruiting No phase listed Observational

A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC

NCT03661866
View directory record Official record
Conditions
Atopic Dermatitis, Alopecia Areata, Hidradenitis Suppurativa, Vitiligo, Psoriasis, Chronic Spontaneous Urticaria
Interventions
Not listed
Lead sponsor
Target PharmaSolutions, Inc.
Industry
Eligibility
Not listed
Enrollment
15,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2050
U.S. locations
54
States / cities
Scottsdale, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 48 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Oct 23, 2026, 11:52 AM EDT
Completed Not applicable Interventional

A Clinical Study to Evaluate the Safety and Efficacy of a Baby Cleanser and a Moisturizer

NCT03719742
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Sponsor Test Products
Other
Lead sponsor
Burt's Bees Inc.
Industry
Eligibility
6 Months to 7 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Richardson, Texas
Source: ClinicalTrials.gov public record
Updated Apr 19, 2019 · Synced Oct 23, 2026, 11:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of Single and Multiple Doses of VAK694 in Healthy and Atopic Subjects

NCT00620230
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
NVP-VAK694
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 60 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
North Miami Beach, Florida
Source: ClinicalTrials.gov public record
Updated Sep 27, 2010 · Synced Oct 23, 2026, 11:52 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions

NCT01931644
View directory record Official record
Conditions
All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis, Asthma, Atopic Dermatitis Eczema, Beta Thalassemia, Bipolar Disorder, Breast Cancer, Celiac Disease, Cervical Cancer, Chronic Inflammatory Demyelinating Polyneuropathy, Chronic Kidney Diseases, Chronic Obstructive Pulmonary Disease, Colon Cancer, Colorectal Cancer, Crohn's Disease, Cystic Fibrosis, Depression, Diabetes Mellitus, Duchenne Muscular Dystrophy, Endometriosis, Epilepsy, Facioscapulohumeral Muscular Dystrophy, G6PD Deficiency, General Anxiety Disorder, Hepatitis B, Hereditary Hemorrhagic Telangiectasia, HIV/AIDS, Human Papilloma Virus, Huntington's Disease, Idiopathic Thrombocytopenic Purpura, Insomnia, Kidney Cancer, Leukemia, Lung Cancer, Lupus Nephritis, Lymphoma, Melanoma, Multiple Myeloma, Multiple Sclerosis, Myositis, Myotonic Dystrophy, Ovarian Cancer, Pancreatic Cancer, Parkinson's Disease, Polycystic Kidney Diseases, Prostate Cancer, Psoriasis, Psoriatic Arthritis, Rosacea, Scleroderma, Sickle Cell Anemia, Sickle Cell Trait, Sjogren's Syndrome, Skin Cancer, Spinal Muscular Atrophy, Systemic Lupus Erythematosus, Thrombotic Thrombocytopenic Purpura, Trisomy 21, Ulcerative Colitis
Interventions
Not listed
Lead sponsor
Sanguine Biosciences
Industry
Eligibility
18 Years to 100 Years
Enrollment
17,667 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 18, 2024 · Synced Oct 23, 2026, 11:52 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Evaluation of the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution

NCT05815758
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution (Combo), Vehicle of brimonidine tartrate 0.025%/ketotifen fumarate 0.035% ophthalmic solution
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
5 Years and older
Enrollment
512 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
7
States / cities
Chandler, Arizona • Havre de Grace, Maryland • Andover, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2025 · Synced Oct 23, 2026, 11:52 AM EDT
Completed Phase 1 Interventional Results available

Clinical Effect, Safety and Tolerability of GSK1070806 in Atopic Dermatitis

NCT04975438
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
GSK1070806, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
8
States / cities
North Little Rock, Arkansas • Miami, Florida • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Oct 23, 2026, 11:52 AM EDT
Recruiting Phase 3 Interventional

An Efficacy and Safety Study of DFL24498 in the Treatment of AKC

NCT07395232
View directory record Official record
Conditions
Atopic Keratoconjunctivitis
Interventions
DFL24498, Vehicle, dexamethasone sodium phosphate (DSP) ophthalmic solution
Drug
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
10 Years to 65 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
8
States / cities
Jacksonville, Florida • Miami, Florida • Morrow, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 23, 2026, 11:52 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Using a Telemedicine Approach in a Genome-wide Association Study of Atopic Dermatitis - Searching for Novel Biomarkers in Clinically Relevant Phenotypes

NCT04965233
View directory record Official record
Conditions
Atopic Dermatitis, Eczema, DNA
Interventions
DNA reports, Information reports
Behavioral
Lead sponsor
Studies&Me
Industry
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated Sep 20, 2021 · Synced Oct 23, 2026, 11:52 AM EDT
Recruiting No phase listed Observational

Monitoring Pregnancy and Infant Outcomes Following Tralokinumab Exposure During Pregnancy in the US and Canada - PROTECT

NCT05938478
View directory record Official record
Conditions
Atopic Dermatitis, Eczema
Interventions
Tralokinumab
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
Female only
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2035
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Oct 23, 2026, 11:52 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Study the Safety and Efficacy of DBI-001 Gel Versus Aqueous Gel

NCT05253755
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
DBI-001, Aqueous gel
Biological
Lead sponsor
DermBiont, Inc.
Industry
Eligibility
12 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
3
States / cities
Scottsdale, Arizona • Austin, Texas • Mill Creek, Washington
Source: ClinicalTrials.gov public record
Updated Nov 8, 2023 · Synced Oct 23, 2026, 11:52 AM EDT
Active, not recruiting No phase listed Observational

Microbiome, Atopic Disease, Prematurity

NCT04835935
View directory record Official record
Conditions
Atopy, Prematurity
Interventions
microbiome pattern
Other
Lead sponsor
Sydney Leibel
Other
Eligibility
0 Days to 7 Days
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
2
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 6, 2025 · Synced Oct 23, 2026, 11:52 AM EDT
Terminated Phase 1Phase 2 Interventional

Ultraviolet (UVA and UVB) Light Therapy in the Treatment of Inflammatory Skin Conditions

NCT00129415
View directory record Official record
Conditions
Atopic Dermatitis, Psoriasis, Alopecia, Mycosis Fungoides, Urticaria, Dermatoses, Stretch Marks
Interventions
UVA1 Irradiation, UVB Irradiation
Procedure
Lead sponsor
University of Michigan
Other
Eligibility
10 Years to 80 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2011
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 22, 2015 · Synced Oct 23, 2026, 11:52 AM EDT
Recruiting Phase 2 Interventional

A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis

NCT07599813
View directory record Official record
Conditions
Atopic Dermatitis, Atopic, Dermatitis, Dermatitis, Atopic, Dermatologic Disease, Eczema, Eczema Atopic Dermatitis, Eczema, Atopic
Interventions
Camoteskimab, Placebo
Drug
Lead sponsor
Apollo Therapeutics Ltd
Industry
Eligibility
18 Years to 65 Years
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
33
States / cities
Birmingham, Alabama • Phoenix, Arizona • Bryant, Arkansas + 26 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 23, 2026, 11:52 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of CD2027 Ointment 3 Microgram Per Gram (mcg/g) Twice Daily Treatment for Adults With at Least Moderate Atopic Dermatitis

NCT00919763
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
CD2027 Ointment 3 mcg/g, twice daily, Vehicle Ointment, twice daily
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
14
States / cities
Hot Springs, Arkansas • San Diego, California • Denver, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2022 · Synced Oct 23, 2026, 11:52 AM EDT
Completed Not applicable Interventional Results available

To Evaluate the Safety and Efficacy of a New Device in the Management of Mild to Moderate Atopic Dermatitis in Children

NCT00886587
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
F# 11054-010, F# 10495-053
Device
Lead sponsor
Johnson & Johnson Consumer and Personal Products Worldwide
Industry
Eligibility
2 Years to 12 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
2
States / cities
Colorado Springs, Colorado • Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated May 23, 2017 · Synced Oct 23, 2026, 11:52 AM EDT
Recruiting Phase 3 Interventional

A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema

NCT06807281
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Abrocitinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
2 Years to 11 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
11
States / cities
Birmingham, Alabama • North Little Rock, Arkansas • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 23, 2026, 11:52 AM EDT